Royal Bank of Canada’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.94M Sell
219,358
-3,492
-2% -$66K ﹤0.01% 2804
2026
Q1
$4.85M Buy
222,850
+15,888
+8% +$308K ﹤0.01% 2440
2025
Q4
$4.45M Sell
206,962
-31,478
-13% -$663K ﹤0.01% 2514
2025
Q3
$4.59M Sell
238,440
-250,236
-51% -$4.46M ﹤0.01% 2744
2025
Q2
$8.36M Sell
488,676
-54,707
-10% -$2.33M ﹤0.01% 2158
2025
Q1
$34.7M Sell
543,383
-29,314
-5% -$3.09M 0.01% 984
2024
Q4
$69.6M Sell
572,697
-13,292
-2% -$1.63M 0.01% 701
2024
Q3
$73.2M Buy
585,989
+90,449
+18% +$12.5M 0.01% 656
2024
Q2
$78.3M Buy
495,540
+34,934
+8% +$4.49M 0.02% 603
2024
Q1
$59.6M Sell
460,606
-353,423
-43% -$43.3M 0.01% 714
2023
Q4
$78.5M Buy
814,029
+365,234
+81% +$35M 0.02% 602
2023
Q3
$54.4M Buy
448,795
+16,051
+4% +$1.81M 0.01% 662
2023
Q2
$49.6M Buy
432,744
+75,504
+21% +$9.74M 0.01% 705
2023
Q1
$49.2M Buy
357,240
+51,945
+17% +$6.74M 0.01% 679
2022
Q4
$39.6M Buy
305,295
+211,138
+224% +$24.5M 0.01% 771
2022
Q3
$10.4M Sell
94,157
-5,087
-5% -$513K ﹤0.01% 1502
2022
Q2
$7.44M Buy
99,244
+30,517
+44% +$2.25M ﹤0.01% 1782
2022
Q1
$5.37M Sell
68,727
-4,867
-7% -$373K ﹤0.01% 2200
2021
Q4
$6.63M Sell
73,594
-8,901
-11% -$761K ﹤0.01% 2193
2021
Q3
$7.63M Sell
82,495
-101,433
-55% -$7.81M ﹤0.01% 2012
2021
Q2
$14.3M Buy
183,928
+127,243
+224% +$9.65M ﹤0.01% 1577
2021
Q1
$4.22M Sell
56,685
-16,572
-23% -$1.53M ﹤0.01% 2371
2020
Q4
$12.5M Sell
73,257
-44,319
-38% -$6.57M ﹤0.01% 1553
2020
Q3
$16.5M Buy
117,576
+11,716
+11% +$1.78M 0.01% 1205
2020
Q2
$17M Buy
105,860
+32,025
+43% +$4.36M 0.01% 1129
2020
Q1
$7.22M Sell
73,835
-24,221
-25% -$2.77M ﹤0.01% 1558
2019
Q4
$12.7M Buy
98,056
+16,563
+20% +$1.67M ﹤0.01% 1459
2019
Q3
$6.14M Buy
81,493
+4,874
+6% +$576K ﹤0.01% 1930
2019
Q2
$11.6M Sell
76,619
-341
-0.4% -$41.4K ﹤0.01% 1449
2019
Q1
$9.17M Sell
76,960
-46,918
-38% -$6.03M ﹤0.01% 1576
2018
Q4
$13.5M Sell
123,878
-26,565
-18% -$3.32M 0.01% 1259
2018
Q3
$24.3M Sell
150,443
-7,385
-5% -$1.01M 0.01% 998
2018
Q2
$20.9M Sell
157,828
-131,066
-45% -$12.4M 0.01% 1046
2018
Q1
$21.4M Sell
288,894
-6,428
-2% -$429K 0.01% 1052
2017
Q4
$16.4M Buy
295,322
+209,373
+244% +$11.1M 0.01% 1262
2017
Q3
$3.9M Buy
85,949
+72,897
+559% +$2.91M ﹤0.01% 2170
2017
Q2
$440K Sell
13,052
-5,104
-28% -$166K ﹤0.01% 3750
2017
Q1
$538K Buy
18,156
+12,009
+195% +$372K ﹤0.01% 3582
2016
Q4
$168K Buy
6,147
+3,256
+113% +$131K ﹤0.01% 4590
2016
Q3
$177K Sell
2,891
-1,115
-28% -$33.7K ﹤0.01% 4511
2016
Q2
$76K Buy
4,006
+405
+11% +$7.5K ﹤0.01% 4902
2016
Q1
$71K Sell
3,601
-3,428
-49% -$59.9K ﹤0.01% 4943
2015
Q4
$271K Buy
7,029
+152
+2% +$4.93K ﹤0.01% 4307
2015
Q3
$221K Buy
6,877
+2,587
+60% +$87.8K ﹤0.01% 4240
2015
Q2
$131K Sell
4,290
-135
-3% -$2.76K ﹤0.01% 4670
2015
Q1
$58K Sell
4,425
-395
-8% -$5.26K ﹤0.01% 4900
2014
Q4
$70K Buy
4,820
+2,494
+107% +$42.2K ﹤0.01% 4901
2014
Q3
$48K Sell
2,326
-20
-0.9% -$451 ﹤0.01% 4971
2014
Q2
$70K Buy
2,346
+60
+3% +$1.9K ﹤0.01% 4699
2014
Q1
$55K Hold
2,286
﹤0.01% 4822
2013
Q4
$46K Sell
2,286
-233
-9% -$6.92K ﹤0.01% 4929
2013
Q3
$119K Buy
2,519
+20
+0.8% +$770 ﹤0.01% 4374
2013
Q2
$95K Buy
+2,499
New +$89.4K ﹤0.01% 4334

Other funds holding SRPT

Royal Bank of Canada's SRPT Position: Q2 2026 in Review

Royal Bank of Canada reduced its Sarepta Therapeutics (SRPT) stake by 1.6% in Q2 2026, selling an estimated $66K and leaving 219,358 shares worth $3.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2804.

Royal Bank of Canada first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $78.5M in Q4 2023. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Royal Bank of Canada held 219,358 shares of Sarepta Therapeutics worth $3.94M as of Q2 2026.
  • Royal Bank of Canada sold 3,492 Sarepta Therapeutics shares in Q2 2026, an estimated $66K.
  • Sarepta Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #2804 holding.
  • Royal Bank of Canada first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Royal Bank of Canada's Sarepta Therapeutics position peaked at $78.5M in Q4 2023.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.